文献速递心律失常心力衰竭与心肌病

UNTOUCHED试验主要结果:S-ICD在低射血分数一级预防患者中的表现

Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial.
PubMed 文献 · Circulation · 2020-10-19

UNTOUCHED试验评估了使用标准化编程和增强鉴别算法的第二代或第三代S-ICD在射血分数≤35%且无起搏适应症的一级预防患者中的不恰当放电率。共1116例患者尝试植入,1111例纳入分析,18个月无IAS生存率为95.9%(置信下限94.8%),1年不恰当放电率为3.1%,全因放电无生存率为90.6%,达到预设性能目标。

要点

  • 18个月无IAS率为95.9%,1年不恰当放电率3.1%,为S-ICD报道的最低值。
  • 全因放电无生存率90.6%,达到预设85.8%的性能目标。
  • 恰当 discrete episodes转复成功率98.4%,18个月无并发症率92.7%。

核心结论

  • 当代S-ICD装置及编程在合并症较多的一级预防患者中表现出高效性和安全性,不恰当放电率低于许多经静脉ICD研究。

研究设计与样本

  • 多中心前瞻性单臂试验,纳入左心室射血分数≤35%且无起搏适应症的一级预防患者,植入第二代或第三代S-ICD,随访18个月。
  • 共1116例患者尝试植入,1111例纳入植入后随访分析;平均年龄55.8±12.4岁,女性25.6%,黑人23.4%,缺血性心脏病53.5%,有症状心衰87.7%,平均LVEF 26.4±5.8%。

主要发现

  • 18个月无不恰当放电生存率为95.9%(置信下限94.8%),1年不恰当放电率为3.1%。
  • 18个月全因放电无生存率为90.6%(置信下限89.0%),达到预设性能目标85.8%。
  • 恰当 discrete episodes的转复成功率为98.4%,18个月无并发症率为92.7%。
  • 降低不恰当放电发生率的预测因素包括:植入最新一代装置、采用三切口技术、无房颤病史和缺血性病因。

关键数值与推荐

  • 主要终点为无不恰当放电率,与基于MADIT-RIT研究中ICD-only患者结果的91.6%性能目标进行比较。
  • 装置编程为:频率≥250次/分时基于频率的治疗发放,频率≥200且<250次/分时形态学鉴别。

临床怎么用

  • 对于左心室射血分数≤35%且无起搏适应症的一级预防患者,可考虑使用当代S-ICD并采用标准化编程以降低不恰当放电。
  • 植入时采用三切口技术、选择最新一代装置可能进一步减少不恰当放电。

局限性

  • 单臂试验设计,无同期对照组,主要终点与外部性能目标比较。
  • 随访时间18个月,长期效果需进一步观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The subcutaneous (S) implantable cardioverter-defibrillator (ICD) is safe and effective for sudden cardiac death prevention. However, patients in previous S-ICD studies had fewer comorbidities, had less left ventricular dysfunction, and received more inappropriate shocks (IAS) than in typical transvenous ICD trials. The UNTOUCHED trial (Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction) was designed to evaluate the IAS rate in a more typical, contemporary ICD patient population implanted with the S-ICD using standardized programming and enhanced discrimination algorithms. METHODS: Primary prevention patients with left ventricular ejection fraction ≤35% and no pacing indications were included. Generation 2 or 3 S-ICD devices were implanted and programmed with rate-based therapy delivery for rates ≥250 beats per minute and morphology discrimination for rates ≥200 and <250 beats per minute. Patients were followed for 18 months. The primary end point was the IAS-free rate compared with a 91.6% performance goal, derived from the results for the ICD-only patients in the MADIT-RIT study (Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy). Kaplan-Meier analyses were performed to evaluate event-free rates for IAS, all-cause shock, and complications. Multivariable proportional hazard analysis was performed to determine predictors of end points. RESULTS: S-ICD implant was attempted in 1116 patients, and 1111 patients were included in postimplant follow-up analysis. The cohort had a mean age of 55.8±12.4 years, 25.6% were women, 23.4% were Black, 53.5% had ischemic heart disease, 87.7% had symptomatic heart failure, and the mean left ventricular ejection fraction was 26.4±5.8%. Eighteen-month freedom from IAS was 95.9% (lower confidence limit, 94.8%). Predictors of reduced incidence of IAS were implanting the most recent generation of device, using the 3-incision technique, no history of atrial fibrillation, and ischemic cause. The 18-month all-cause shock-free rate was 90.6% (lower confidence limit, 89.0%), meeting the prespecified performance goal of 85.8%. Conversion success rate for appropriate, discrete episodes was 98.4%. Complication-free rate at 18 months was 92.7%. CONCLUSIONS: This study demonstrates high efficacy and safety with contemporary S-ICD devices and programming despite the relatively high incidence of comorbidities in comparison with earlier S-ICD trials. The inappropriate shock rate (3.1% at 1 year) is the lowest reported for the S-ICD and lower than many transvenous ICD studies using contemporary programming to reduce IAS. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02433379.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Gold MR, Lambiase PD, El-Chami MF, et al. Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. Circulation. 2020. PMID: 33073614. doi:10.1161/CIRCULATIONAHA.120.048728

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。